Future of MediBio, page-3

@Monster_User some valid points and considerations for the business to at least at a minimum think about and consider the current engagement and messaging with the market and how they will choose to moving forward.

I understand that Dave is in the country next week meeting with a number of existing shareholders, prospective new shareholders and brokers / advisers / asset managers to re-engage a relationship, try to repair some of the damage that was done under the previous management and get off on the right foot in forming a relationship to assist with advancing MEB at a corporate and market engagement / awareness level. I think NWR communications out of Melb is assisting with Dave's schedule, so for those wanting a meeting, it would be worth making contact to see what his travel plans are and availability.

I think all shareholders can agree that hopefully this is the start of something positive for the business and we see on market the results of these meetings.

Iam under no illusion that delivery and execution of strategy is the best thing the business can do to instill confidence and show the market that the business is moving forward and on track to deliver on the regulatory front and continual commercialization plans.

Just having a quick loo through your suggestions, i've included a couple of thoughts:

- Next time please prepare a proper Investor Presentation with clear short & long term milestones and going forward company strategy to achieve those targets. Also include the breakdown of cash spend with categories. Don’t hide spends in professional consulting or legal buckets.

If investors are wanting this level of detail, there's no harm in asking for it. I think now that Dave is in the business and been through the capital raise and re-structuring, he will have a better idea of short / medium term targets for the business.

- Get Dave, Melanie, Michael Phelps on the road show to meet existing top 5 shareholders and potential new shareholders/ Brokers.

Do agree here, they can make better use out of the company's resources to assist with shareholder and market engagement. However at the end of the day, the business will really be judged by its ability to execute and deliver on strategy. As much as i'd like to meet these people and would give them my time at the end of the day it's irrelevant, all i really care about is seeing the business delivery the strategy.

- Company have lost credibility due to poor performance in last 9 months. Company needs to provide more honest, insight and transperancy to the shareholders.

I think we can all agree that there were multiple issues and factors at play that contributed to the significant destruction in shareholder wealth and confidence in the business. Regardless of where the blame lies. Any one of those issues that placed out in the second half of last year were significant in their own right. Iam comfortable that certain people that contributed to these various issues are no longer with the business and all we can do as shareholders is move forward from this, try and put it behind us and focus on either assisting the business from a market engagement level or strategy delivery perspective if we choose to.

- Reduce the number of Board members and Executives. A company with a market capital of 4 million and cash at bank of less than $2 million don’t need this many executives.

Iam comfortable that the current BOD have chosen to forgo payment for their services as a cash consideration and I would expect that any person on the Board is contributing to moving the business forward to delivering on the strategy. I think what played out last year and the 249D was a wake up call and really with all the fiduciary obligations / personal liabilities attached, no Board member would choose to be a passenger. It will be interesting to see if any of the current Board choose to leave in the current FY.

- Please don’t completely rely on shareholders and keep raising funds. We have already contributed a lot. MediBio should also focus on generating some revenue from its existing ready to market services.

Do agree. Whilst i am encouraged at the level of commitment shown by the Top#20 (and those that participated in the rights issue) to continue to fund the business, those that have chosen to exit the register (like IFM Investors), have every right to and who can really blame them for wanting to exit and move on. I certainly think that many that choose not to participate in the rights issue are adopting a wait and see approach and may choose to increase their position at a later date, should they have confidence that the strategy is being delivered. It was never a question of how cheap the raise was to encourage commitment, it was completely about having faith in the new CEO and Board to actually deliver on milestones.

- No one knows how much we have spend on ilumen so far ???? What sort of revenue are we expecting in 2019, 2020 and 2021 ????? Projected revenue ??? What is company strategy to commercialise and generate revenue from ilumen ?

I do agree that it would be in the company's best interest to share some information to the market / shareholders in regards to the Illumen product. I don't have an issue with outsourcing the clinician component of this business at it removes a layer of overheads and takes the decision around having to scale up / employ more resources away from the business should the AIA pilot turn into a meaningful contract the business needs to service. Deriving revenue from billable hours to clinicians IMO isn't a highly profitable business, once all expenses are paid.

- Previous Investor Presentation was very poorly written.Expected spend in 2019 is approx 7 million and all we are expecting is ‘one or more FDA 510K application clearance and response to De Nova FDA application response’ and No commercialisation or roll out plan for FDA 510K cleared services.

Iam personally expecting more from Dave and the team here. It would be very useful for the group to put together a strategy that involves commercializing the product in Australia and Europe, where regulatory approval is already granted. I don't think shareholders will stomach having a binary outcome in regards to the business being successful in the short term reliant of FDA approval (DeNovo or 510k).

- Ensure to not to write such wordings like raising from Convertible notes will be sufficient for 12 months. Is this mean that Company will run out of money again and will be raising more $$$.

Do understand where you are coming from. Always challenging for a company to manage messaging around these things. I don't think i comes as any surprise for a business that is not cash flow positive the eventual need to raise funds into the future.

- Previously company had failed to stop the share price from falling due to lack of transparency, heavily cash burn and poor performance. It’s company responsibility to keep providing market with some positive news and to give a clear message that everything is under control and Directors and Executives have stopped playing musical chair game now.

As much as I would like a company to continually release positive news to help reinforce confidence, it's simply not possible. A CEO / Board of a listed company need to ensure that the market is kept fully informed in regards to events (material / non material) that affect the business, no matter how negative these events may be. Whilst there is plenty of grey area around non material events, i think it would be in the company's best interest, especially whilst Dave is located in the US to share relevant information / updates that don't make there way to market via an announcement possibly via a qtrly investor call like we used to have.